Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J I Weitz

Showing results (21-30 of 136) with videos related to

Pageof 14
Sort By:
Thrombosis and Haemostasis|July 26, 2013
Dabigatran monitoring made simple?J W Eikelboom, J I Weitz
The Journal of Invasive Cardiology|January 13, 2001
Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventionsN S Kleiman, J I Weitz
The Journal of Invasive Cardiology|January 13, 2001
The mechanism of action of thrombin inhibitorsS M Bates, J I Weitz
Journal of Thrombosis and Haemostasis : JTH|August 27, 2014
Guidance, guidelines, and communicationsJ D Douketis, J I Weitz
Coronary Artery Disease|July 1, 1998
The new heparinsS M Bates, J I Weitz
Journal of Thrombosis and Haemostasis : JTH|August 17, 2005
New anticoagulantsJ I Weitz, S M Bates
Clinical Pharmacology and Therapeutics|June 26, 2009
New antithrombotic drugsP L Gross, J I Weitz
Circulation|March 11, 1998
Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitorsJ I Weitz, B Leslie, M Hudoba
The Journal of Clinical Investigation|March 1, 1991
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysisJ I Weitz, B Leslie, J Ginsberg
Biology of the Neonate|January 1, 1990
Effect of fibrinogen degradation products and lung ground substance on surfactant functionH M O'Brodovich, J I Weitz, F Possmayer
Pageof 14

Showing results (21-30 of 136) with videos related to

Sort By:
Pageof 14
Thrombosis and Haemostasis|July 26, 2013
Dabigatran monitoring made simple?J W Eikelboom, J I Weitz
The Journal of Invasive Cardiology|January 13, 2001
Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventionsN S Kleiman, J I Weitz
The Journal of Invasive Cardiology|January 13, 2001
The mechanism of action of thrombin inhibitorsS M Bates, J I Weitz
Journal of Thrombosis and Haemostasis : JTH|August 27, 2014
Guidance, guidelines, and communicationsJ D Douketis, J I Weitz
Coronary Artery Disease|July 1, 1998
The new heparinsS M Bates, J I Weitz
Journal of Thrombosis and Haemostasis : JTH|August 17, 2005
New anticoagulantsJ I Weitz, S M Bates
Clinical Pharmacology and Therapeutics|June 26, 2009
New antithrombotic drugsP L Gross, J I Weitz
Circulation|March 11, 1998
Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitorsJ I Weitz, B Leslie, M Hudoba
The Journal of Clinical Investigation|March 1, 1991
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysisJ I Weitz, B Leslie, J Ginsberg
Biology of the Neonate|January 1, 1990
Effect of fibrinogen degradation products and lung ground substance on surfactant functionH M O'Brodovich, J I Weitz, F Possmayer
Pageof 14